Kevin Plancher, MD, is a board-certified orthopedic surgeon and founder of Plancher Orthopaedics & Sports Medicine in New York City and Greenwich, Conn. Here are his insights on joint replacement versus growth factors and stem cell therapy for the treatment of hip and knee pain.

SpinalCyte filed an Investigational New Drug Application with the FDA to expand its study of CybroCell Human Dermal Fibroblasts for the treatment of degenerative disc disease.

The orthopedic biomaterials market is growing as the U.S. population ages, according to a Transparency Market Research report.

The American Academy of Orthopaedic Surgeons collaborated with the National Institutes of Arthritis, Musculoskeletal, and Skin Diseases to hold a symposium Feb. 15 through Feb. 17 at Stanford (Calif.) University on optimizing the use of biologics in orthopedic surgery.

The global spinal biologics market is expected to reach $2.4 billion by 2020, according to a MarketsandMarkets report. Here are eight companies leading the spinal biologics field.

Adam W. Anz, MD, is an orthopedic surgeon and sports medicine specialist at Gulf Breeze, Fla.-based Andrews Institute for Orthopaedics & Sports Medicine. He is the director of the Andrews Institute Regenerative Medicine Center and oversees the ATC Fellowship Program at the Andrews Research & Education Foundation, where he serves as a board member.

RTI Surgical accomplished a major milestone in April.

Here are 14 developments in spinal biologics in 2018 so far.

Patients who received intradiscal injections of SpinalCyte's new cell-based therapy CybroCell showed significantly improved disc height after six months.

Regenerative medicine company Mesoblast completed enrollment for its Phase 3 mesenchymal cell therapy trial to treat chronic low back pain due to degenerative disc disease.

The global orthobiologics market is predicted to exceed $5.52 billion in 2019, according to Transparency Market Research.

DiscGenics presented results from two preclinical studies assessing its IDCT product, a homologous, allogenic, injectable cell therapy.

Three spine surgeons from across the U.S. discuss where they see the biggest opportunities in spinal biologics and disc generation.

Aziyo Biologics launched OsteGro, an allograft bone matrix designed to support new bone growth in procedures such as hip reconstruction, bone fracture repair and spinal fusion.

Indianapolis-based orthopedic surgeon Greg Merrell, MD, treated the first U.S. patient in Cartiva's GRIP 2 study, evaluating the safety and effectiveness of the Cartiva Synthetic Cartilage Implant to treat osteoarthritis of the thumb. 

The global stem cell therapy market is projected to grow at a compound annual growth rate of 36.52 percent between 2017 and 2021, according to an analysis by Wise Guy Reports.

KICVentures acquired Amend Surgical, a company developing synthetic bioactive glass products.

Orthobiologics company Cerapedics received FDA approval to initiate a study of P-15L Peptide Enhanced Bone Graft compared to autograft in transforaminal lumbar interbody fusion surgery for degenerative disc disease.

Gregory Lutz, MD, and Kevin Pauza, MD, launched a new study to examine the clinical effectiveness of Discseel, a treatment to restore and regrow damaged discs in the spine.

Mesenchymal stromal cells have shown promise for regenerative medicine, according to the Journal of Orthopaedics. They may improve spinal fusion.